A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia

A phase II randomized trial of sodium oligomannate in Alzheimer’s dementia

Abstract Background Sodium oligomannate (GV-971), a marine-derived oligosaccharide, is a novel agent that may improve cognition in AD patients. Methods The 24-week multicenter, randomized, double-blind, placebo parallel controlled clinical trial was conducted in AD in China between 24 October 2011 a...

Full description

Bibliographic Details
Main Authors: Tao Wang, Weihong Kuang, Wei Chen, Wenwei Xu, Liming Zhang, Yingjie Li, Hailin Li, Ying Peng, Yangmei Chen, Baojun Wang, Jinsong Xiao, Honghua Li, Chuanzhu Yan, Yifeng Du, Mouni Tang, Zhiyi He, Haibo Chen, Wei Li, Hong Lin, Shugui Shi, Jianzhong Bi, Huadong Zhou, Yan Cheng, Xiaoping Gao, Yihui Guan, Qiu Huang, Kewei Chen, Xianliang Xin, Jian Ding, Meiyu Geng, Shifu Xiao
Format: Article
Language:English
Published: BMC 2020-09-01
Series:Alzheimer’s Research & Therapy
Subjects:
Sodium oligomannate
Efficacy
Safety
Alzheimer’s disease
Clinical trial
Online Access:http://link.springer.com/article/10.1186/s13195-020-00678-3

Internet

http://link.springer.com/article/10.1186/s13195-020-00678-3

Similar Items